393(b)(2)(C) and 42 U.S.C. 300u–1), FDA and the Fred Hutchinson Cancer Research Center in Seattle, WA, have jointly designed a study involving a written survey to be completed by women with a previous diagnosis of endometrial cancer. The study will evaluate the occurrence of menopausal vasomotor symptoms (''hot flashes'') among these women, and the extent to which they have used HRT, either as therapy for menopausal symptoms or for other reasons. (''Hormone replacement therapy'' means treatment with estrogen alone or with a combination of estrogen and progestogen.)

FDA estimates the burden of this survey as follows:

ESTIMATED ANNUAL REPORTING BURDEN

No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
575	1	575	.5	288

There are no capital costs or operating and maintenance costs associated with this collection.

Dated: June 26, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–16884 Filed 7–2–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0186]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995, Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed survey of mammography facilities to assess the impact of proposed regulations required by the Mammography Quality Standards Act of 1992 (the MQSA).

DATES: Submit written comments on the collection of information by September 3, 1996.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Charity B. Smith, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c). To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

FDA Survey of Mammography Facilities

The MQSA of 1992 (Pub. L. 102–539) has resulted in regulatory efforts by FDA to ensure high quality standards for mammography in the United States. In the Federal Register of April 3, 1996 (61 FR 14856), FDA proposed final regulations to implement these standards. Interim regulations are codified at 21 CFR 900. In connection with this rulemaking, FDA proposes to conduct a survey of facilities to determine current operating costs and procedures. The information to be collected from the proposed survey includes general provider characteristics, equipment characteristics, facility operating procedures, personnel qualifications, and costs of compliance with current quality standards. This information is necessary in order to ensure that costs to affected facilities are minimized to the extent consistent with maintenance of high quality mammography services, and that patient access to mammography services is not diminished as a result of agency action.

The proposed survey will be a one-time data collection effort. Surveys will be mailed to 1,000 randomly selected facilities. Facilities will be contacted by telephone in order to respond to any specific issues, or questions that may arise. Responses will not be mandatory, and no facility will be required to respond. All responses will be kept confidential, although a compilation of data that does not reveal facility-specific information will be made available upon request to participants and to the public. A toll-free telephone number will be installed to allow respondents the opportunity to call if specific issues arise.

FDA estimates the burden of this one-time survey as follows:

ESTIMATED ANNUAL REPORTING BURDEN

Burden Element	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Costs
Initial Contact by Telephone	1,000	1	1,000	0.083	83	$1,385
Compile Requested Information	702	1	702	1.0	702	$11,716

ESTIMATED ANNUAL REPORTING BURDEN—Continued

Burden Element	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Costs
Mail-in Response	200	1	200	0	N/A	N/A
Telephone Followup	800	1	800	0.083	67	$1,118
Responses by Telephone Interview	480	1	480	0.5	240	$4,006
Mail-In Response After Receiving Followup	22	1	22	0	N/A	N/A
Total Burden					1,092	$18,225

There are no capital costs or continuing operating and maintenance costs associated with this survey. These burden estimates include the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the collection of information. The hour and cost burden estimates were derived from a pretest of nine randomly selected facilities.

Dated: June 26, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–16970 Filed 7–2–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0121]

Bayer Corp., et al.; Withdrawal of Approval of 29 NADA's

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 29 new animal drug applications (NADA's). Twenty-four NADA's are held by Bayer Corp., Agriculture Division, Animal Health (formerly Miles, Inc., Agriculture Division, Animal Health Products), three are held by Hubbard Milling Co., and one each is held by Hoffmann-LaRoche, Inc., and Ohmeda, Inc. The firms notified the agency in writing that the animal drug products are not being manufactured or marketed and requested that approval of the applications be withdrawn. In a final rule published elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations by removing the entries which reflect approval of the NADA's.

EFFECTIVE DATE: July 15, 1996.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0159.

SUPPLEMENTARY INFORMATION: The sponsors of the applications listed in the table in this document have informed FDA that these animal drug products are not being manufactured or marketed and have requested that FDA withdraw approval of the applications.

NADA no.	Drug name	Sponsor name and address
6–462	Diethylcarbamazine tablets	Bayer Corp., Agriculture Division, Animal Health, P.O. Box 390, Shawnee Mission, KS 66201.
10–540	Calcium disodium edetate injection	Do.
11–380	Diethylcarbamazine powder	Do.
12–054	Protokylol hydrochloride tablets and injection	Do.
12–103	Triamcinolone tablets	Do.
12–392	Triamcinolone injection	Do.
12–598	Disophenol sodium injection	Do.
15–161	Trichlorfon powder	Do.
15–965	Coumaphos Type A medicated article	Do.
30–045	Triamcinolone/neomycin sulfate ointment	Do.
34–394	Niclosamide tablets	Do.
35–263	Styrylpyridinium chloride/diethylcarbamazine (as base) oral liquid.	Do.
45–287	Coumaphos crumbles	Do.
48–645	Tylosin Type A medicated articles (5, 10, 20, and 40 grams per pound).	Hubbard Milling Co., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002–8500.
49–555	Styrylpyridinium chloride/diethylcarbamazine control diet HRH/MSD.	Bayer Corp.
91–628	Diethylcarbamazine citrate syrup	Do.
93–372	Chlortetracycline calcium complex Type A medicated articles.	Hoffmann-LaRoche, Inc., Nutley, NJ 07110.
94–402	Tylosin and sulfamethazine Type A medicated articles	Hubbard Milling Co.
95–078	Trichlorfon oral liquid	Bayer Corp.
96–031	Styrylpyridinium chloride/diethylcarbamazine citrate tablets.	Do.
100–201	Trichlorfon paste	Do.
100–356	Styrylpyridinium chloride/diethylcarbamazine control diet HRH.	Do.
100–670	Niclosamide Type A medicated article	Do.
101–078	Dichlorophene and toluene capsules	Do.
120–327	Diethylcarbamazine chewable tablets	Do.
120–670	Styrylpyridinium, diethylcarbamazine edible tablets	Do.